Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial

NCT01372644 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT01372644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01372644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial
Lead sponsor
NYU Langone Health
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2007
Completion date
November 30, 2013
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atypical ductal breast hyperplasia, atypical lobular hyperplasia (alh) of breast, lobular carcinoma in situ (lcis)